Analysis from the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58) on the association of baseline HbA1c with cardiovascular and kidney outcomes (Diabetes Care)
Diabetes News
Tag: macrovascular
Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes
Physicians should not be falsely reassured by claims that a new treatment appears to have passed a narrowly-defined regulatory test. The management of diabetic patients often carries with it the risk of important cardiovascular consequences, even for drugs that do not overtly increase the risk of myocardial infarction or stroke (Diabetes, Obesity and Metabolism)
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Treatment with exenatide, with or without concomitant insulin was associated with reduced macrovascular risks compared to insulin; although inherent potential bias in epidemiological studies should be considered
Glycosmedia is also available as an App: